CytoGam Acquisition Strengthens ZLB Behring's Immunoglobulin Portfolio
This article was originally published in The Pink Sheet Daily
Executive Summary
MedImmune divests the transplantation treatment to ZLB Behring for an up-front payment of $50 mil.
You may also be interested in...
FDA Faults Cytogam Sales Literature For Unsubstantiated Long-Term Survival Claim
Clinical trial's long-term survival was not statistically significant, agency says in letter to CLS Behring.
FDA Faults Cytogam Sales Literature For Unsubstantiated Long-Term Survival Claim
Clinical trial's long-term survival was not statistically significant, agency says in letter to CLS Behring.
MedImmune Gains Anti-CD28 Biologic In Deal With Japan Tobacco
MedImmune is bolstering its research pipeline for treatments targeting inflammatory diseases, announcing its second licensing deal this month for technology in the therapeutic class. Under the latest deal with Japan Tobacco, announced Dec. 28, the company intends to develop a monoclonal antibody targeting CD28 receptor pathways for treatment of inflammatory diseases